Oncology NEWS International Vol 11 No 12

Tandem Transplants Increase CR, Reduce Treatment Mortality in Multiple Myeloma

December 01, 2002

SEATTLE-A two-stage procedurethat combines high-dose chemotherapywith autologous stemcell transplantation (SCT) with animmunosuppressive (but notmyeloablative) allogeneic SCT inmultiple myeloma improves completeresponse rate and decreasestreatment-related mortality.

Stereotactic Radiosurgery Benefits Brain Met Patients

December 01, 2002

NEW ORLEANS-For certain types of patients with brain metastases, the addition of stereotactic radiosurgery after whole brain radiation therapy improved survival as well as local control, performance status, and steroid dependency, according to a phase III study by the Radiation Therapy Oncology Group (RTOG). Lead investigator Paul W. Sperduto, MD, of Methodist Hospital, Minneapolis, presented the results at the 44th Annual Meeting of the American Society for Therapeutic Radiation and Oncology (abstract plenary 5).

Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Report

December 01, 2002

WASHINGTON-There is insufficient evidence to prove or disprove whether polio vaccine doses contaminated with simian virus-40 (SV40) between 1955 and 1963 can trigger certain cancers in humans, according to a report by the Institute of Medicine (IOM), a part of the National Academy of Sciences. Although most population studies have not found an increase in the cancers among people inoculated with the vaccine between 1955 and 1963, a possible link cannot be completely ruled out because of substantial statistical and design limitations in the 13 studies, an IOM committee concluded.

Tailored Messages Motivate Women to Get Mammograms

December 01, 2002

WASHINGTON-In motivating women to get timely mammograms, discussions tailored to individuals’ particular reasons for not getting mammograms are far more effective than general recommendations, said Diane Ruth Lauver, PhD, RN, professor of women’s health, University of Wisconsin, Madison. Speaking at the American Psychological Association Conference on Enhancing Outcomes in Women’s Health, she reported on a study of motivational messages given to 797 Midwestern women, age 51 to 80, who had not had a mammogram in the past 13 months.

Chemo/Rituximab Is Effective as First-Line CLL Therapy

December 01, 2002

LUGANO, Switzerland-Thechemotherapy/immunotherapy regimenFCR (fludarabine, cyclophosphamide,rituximab) has produced thehighest complete response (CR) rateseen thus far in first-line treatment ofchronic lymphocytic leukemia (CLL),according to investigator Michael J.Keating, MD. The FCR regimen,which is well tolerated, also results inmolecular remissions in a "significantnumber" of complete responders, saidDr. Keating, professor of medicine,M.D. Anderson Cancer Center.

Preoperative Capecitabine/RT Downstages Rectal Cancer

December 01, 2002

TAEJON, Korea-In a study from Korea of patients with locally advanced rectal cancer, preoperative capecitabine (Xeloda) with leucovorin given concurrently with radiotherapy resulted in primary tumor downstaging and nodal downstaging, reported Jun-Sang Kim, MD, of Chungnam National University, Taejon, and colleagues.

Intraoperative Lymphatic Mapping Enhances Cancer Staging

December 01, 2002

SEATTLE-Intraoperative colon-oscopy with lesion tattooing and lymphatic mapping during laparoscopic colectomy can improve accuracy in identifying a small primary colorectal neoplastic lesion and its lymphatic drainage, according to a study presented at the President’s Plenary Session of the 67th Annual Scientific Meeting of the American College of Gastroenterology (ACG abstract 4).

Rituximab Ups Survival in Aggressive and Indolent NHL

December 01, 2002

ORLANDO-Presentations atthe 43rd Annual Meeting of theAmerican Society of Hematology(ASH) showed increased survival forpatients with aggressive and indolentnon-Hodgkin’s lymphoma(NHL) who received the anti-CD20monoclonal antibody rituximab(Rituxan) in addition to standardCHOP chemotherapy (cyclophosphamide,doxorubicin, vincristine,prednisone).

Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial

December 01, 2002

FRAMINGHAM, Massachusetts-Genzyme Molecular Oncology has launched a phase I/II vaccine trial in advanced kidney cancer. The vaccine is made by combining the patient’s own cancer cells with dendritic cells using an electrical fusion approach. Up to 20 patients will be enrolled at Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute, Boston.

Lower Breast Cancer Survival in Hispanics: New Mexico Study

December 01, 2002

ORLANDO-A New Mexico study has found that Hispanic women are more likely than white women to be diagnosed with breast cancer at a younger age, are more likely to be estrogen-receptor (ER) negative, and are at greater risk for poor survival. Diane D. Crumley, PhD, research assistant professor, Division of Epidemiology and Preventive Medicine, University of New Mexico, reported the findings at the Era of Hope Department of Defense Breast Cancer Research Program meeting.

Concurrent Chemo/RT More Likely to Save Larynx

December 01, 2002

NEW ORLEANS-In stage III and low-volume stage IV laryngeal cancer, concurrent chemotherapy and radiotherapy was superior to two other approaches in controlling tumor and preserving the larynx, according to a three-arm Intergroup trial presented at the 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract plenary 4). Moshe H. Maor, MD, of the Radiation Oncology Department, M.D. Anderson Cancer Center, presented the results.

Rituximab Improves Paclitaxel/ Topotecan Salvage Efficacy in NHL

December 01, 2002

O R L A N D O - A d d i n grituximab (Rituxan) to paclitaxel(Taxol)/topotecan (Hycamtin) salvagetherapy raises response rates byabout 25%, more than triples completeresponse rates, and is effectivein both primary refractory and relapsedaggressive B-cell lymphomas.

CT Growth Assessment Reliably Diagnoses Solid Lung Nodules

December 01, 2002

NEW YORK-Computed tomography (CT) screening for lung cancer has revealed subtypes of nodules whose natural histories are being assessed in long-term follow-up, according to Claudia I. Henschke, PhD, MD, director, Division of Chest Imaging, and professor of radiology, Weill Medical College, Cornell University.

Fludarabine Combos Showing Efficacy in Lymphomas

December 01, 2002

LUGANO, Switzerland-For low-grade lymphomas, fludarabine (Fludara)-based combination therapy may have greater efficacy than single-agent flu-darabine, especially when a monoclonal antibody is part of the combination, a series of recent European investigations suggest. The investigations, presented at the Eighth International Conference on Malignant Lymphoma (ICML), show that various combination therapies hold promise, although a lack of coordination among non-US study groups has hampered progress somewhat.

EntreMed’s Thalidomide Analog in Phase I Multiple Myeloma Trial

December 01, 2002

ROCKVILLE, Maryland-En-treMed, Inc. has begun a phase I study of its thalidomide derivative ENMD 0995 at the Mayo Clinic, Rochester, Minnesota, in patients with multiple myeloma. ENMD 0995 recently received orphan drug designation from the FDA for the disease.

Postmastectomy RT in Node+ Patients Reduces Locoregional Recurrence

December 01, 2002

NEW ORLEANS-Radiation therapy after mastectomy reduces locore-gional recurrence rates for breast cancer patients with positive lymph nodes, positive surgical margins, or both, according to the results of a large retrospective study presented at the 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO abstract 153).

Opioid Rotation, Methadone Urged for Hard-to-Treat Cancer Pain

December 01, 2002

BOSTON-Most advanced cancer patients suffer from pain that could be relieved with broader use of opioid analgesics, according to Eduardo Bruera, MD, F.T. McGraw Chair in the Treatment of Cancer, M.D. Anderson Cancer Center.

Emergence of Chronic Leukemias as Major Research Targets in Leukemia

December 01, 2002

In the last 20 yearsof the past millennium,most clinical researchin leukemiawas directed towardimproving prognosisof acute leukemia andstudying the role ofstem cell transplantation(SCT), both autologousand allogeneic,in these diseases.The emergence of new treatments and therapeuticapproaches has dramatically changed the emphasisof clinical research in leukemia. The power ofeffective new agents to transform clinical research hasbeen illustrated by the emergence of the tyrosine kinaseinhibitor imatinib mesylate (Gleevec, STI-571) inchronic myeloid leukemia and monoclonal antibodiesin chronic lymphocytic leukemia (CLL).

Feds Fund CAM Use Study

December 01, 2002

WASHINGTON-A 2-year, $1 million study by the Institute of Medicine (IOM) will explore the scientific and policy implications of complementary and alternative medicine (CAM). The study is being funded by 16 units of the National Institutes of Health, including the National Cancer Institute, and the Agency for Healthcare Research and Quality. The IOM, a part of the National Academy of Sciences, will name a committee of about 16 experts to carry out the study. Panel members will be chosen from among leading CAM specialists and more conventional disciplines.

New Tyrosine Kinase Inhibitor More Potent Than STI-571

December 01, 2002

MIAMI BEACH -The Bcr-Abl tyrosine kinase inhibitorPD173955 (PD17) binds to the targetATP binding pocket even moreefficiently than STI-571 (imatinibmesylate, Gleevec). It shows 15 to20 times greater efficacy in chronicmyelogenous leukemia (CML) celllines because it can bind to eitheropen or closed activation loops.

Lifelong Physical Activity Lowers Breast Cancer Risk

December 01, 2002

ORLANDO-Women in all ethnic groups who have spent their lives exercising, performing heavy household chores, or tackling a physically strenuous job had a lower risk of breast cancer than their more sedentary counterparts, according to a poster presented at the Era of Hope Department of Defense Breast Cancer Research Program meeting. "We were pleased with the results," said principal investigator Esther M. John, PhD, director of epidemiology research, Northern California Cancer Center, Union City. "It’s a message we can give women to help prevent breast cancer, and there are other health benefits to physical activity."

Follow-up Colonoscopy Lowers Mortality in Colorectal Cancer Patients

December 01, 2002

SEATTLE-Having at least one follow-up colonoscopy within 5 years of a diagnosis of nonmetastatic colorectal cancer decreased the mortality risk by 40%, according to a study presented at the 67th Annual Scientific Meeting of the American College of Gastroenterology (president’s plenary session abstract 11).

Thalidomide Effective in Newly Diagnosed Multiple Myeloma

December 01, 2002

ROCHESTER, Minnesota-Previous studies have shown the benefits of thalidomide (Thalomid) in patients with relapsed multiple myeloma. Now, researchers from the Mayo Clinic report that the oral combination of thalidomide and dexamethasone is feasible and active as initial therapy of the disease.

Survey Will Help NCI Improve Cancer Communications

December 01, 2002

BETHESDA, Maryland-A national survey, now in progress, will enable the National Cancer Institute (NCI) for the first time to examine the interrelationship of people’s knowledge about cancer, their sources of cancer information, and their cancer-related behavior. The Health Information National Trends Survey (HINTS), a telephone survey of 8,000 randomly selected, representative US adults, began in late October. Data collection is expected to take 5 months.

HRT Is Not Recommended to Treat Chronic Conditions

December 01, 2002

ROCKVILLE, Maryland-An independent advisory board has entered the debate over the safety and efficacy of hormonal replacement therapy (HRT) and recommended against the use of the estrogen/progestin combination in postmenopausal women as a preventive treatment for cardiovascular disease and other chronic conditions. It also concluded that insufficient evidence exists to support a recommendation for or against the use of estrogen alone for preventing chronic conditions in postmenopausal women who have undergone a hysterectomy.

Pegfilgrastim Benefits Elderly Breast Cancer Patients on Chemo

December 01, 2002

BOSTON-Pegfilgrastim (Neu-lasta), the longer-lasting analog of the colony-stimulating factor filgrastim (Neupogen), is safe for elderly breast cancer patients receiving myelosuppressive chemotherapy and protects against febrile neutropenia, according to a poster presented at the third meeting of the International Society of Geriatric Oncology (SIOG abstract P-23).

OraQuick Gets FDA Approval for Rapid Diagnosis of HIV-1

December 01, 2002

ROCKVILLE, Maryland-A quick HIV-1 diagnostic test with high specificity and sensitivity has received conditional approval by the US Food and Drug Administration (FDA) for use in detecting antibodies to the most common form of the virus found in the United States.

NCCN Updates Hodgkin’s Disease Treatment Guidelines

December 01, 2002

HOLLYWOOD, Florida-There were several significant changesto the National Comprehensive CancerNetwork (NCCN) Hodgkin’s diseaseguidelines announced at the SeventhAnnual NCCN Conference (seeTable for NCCN member institutions).

Darbepoetin Alfa Safe, Effective for Elderly Chemo Patients

December 01, 2002

BOSTON-Darbepoetin alfa (Ara-nesp), the new long-lasting erythropoietic agent, is safe and effective for treatment of chemotherapy-induced anemia in older patients, Lodovico Balducci, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, told ONI at the third meeting of the International Society of Geriatric Oncology (SIOG abstract P-12).

Why Women Don’t Return for Mammography Follow-up

December 01, 2002

WASHINGTON-Young women who are depressed, think of themselves as being at low risk for breast cancer, or have relatively painless mammograms are likely to skip diagnostic follow-up, according to Alexis Bakos, PhD, MSN, RN,C. In a podium presentation at the Oncology Nursing Society’s 27th Annual Congress (abstract 10), Dr. Bakos said that 25% to 60% of women do not return for follow-up and that the goal of her study was to determine who does not return, and why.

Median PFS Not Yet Reached After 6 Years in Rituximab/CHOP Trial

December 01, 2002

BUFFALO, New York-Medianprogression-free survival hasstill not been reached after 6 yearsmedian follow-up of 40 patientswith low-grade or follicular non-Hodgkin’s lymphoma (NHL) treatedin the first clinical trial ofrituximab (Rituxan) in combinationwith CHOP (cyclophosphamide[Cytoxan, Neosar], doxorubicinHCl, vincristine [Oncovin],and prednisone), Myron S.Czuczman, MD, reported.

Reducing Breast Cancer Mortality in Poorer Countries

December 01, 2002

SEATTLE, Washington-In a new endeavor, an international group of experts is creating detailed guidelines for the screening, diagnosis, and treatment of breast cancer in countries and regions of the world with limited resources. The endeavor began with the Global Summit Consensus Conference and will lead to the publication, dissemination, and translation of the first edition of the guidelines next year.

Rituximab Improves Efficacy of Chemotherapy for Follicular Lymphomas

December 01, 2002

ORLANDO, Florida-Addingrituximab (Rituxan) to standard chemotherapyfor follicular lymphomaregimens improves the rate and qualityof responses and increases clearanceof the bcl-2/IgH chimeric gene,according to studies from US andItalian cooperative groups reportedat the 43rd Annual Meeting of theAmerican Society of Hematology.

10 Centers Share First Avon ‘Progress for Patients’ Grants

December 01, 2002

BETHESDA, Maryland-Six initial breast cancer research grants totaling $2.5 million have been awarded through the National Cancer Institute-Avon Foundation’s Progress for Patients program to fund innovative translational science at 10 research institutions. The program administers a $20 million pledge from the Avon Foundation. The initial grants consist of $1.99 million from the Avon Foundation and $660,000 from NCI.

Humanized Anti-CCR5 MoAb Blocks HIV Entry: Preclinical Trial

December 01, 2002

SAN DIEGO, California-Pro-genics Pharmaceuticals’ humanized monoclonal antibody (MoAb) PRO 140 has been shown to block HIV entry into immune system cells. The agent acts by binding to a portion of the CCR5 fusion coreceptor present on the outer membrane of immune system cells. William C. Olson, PhD, vice president of research and development at Progenics, Tarry-town, New York, presented the research at the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (abstract H-178).

Modalities for Localized Prostate Cancer Show Equal Failure Rates

December 01, 2002

NEW ORLEANS-In the treatment of localized prostate cancer, biochemical failure rates are similar among permanent radioactive seed implantation, high-dose external beam radiation therapy, combination seeds/external radiation, and radical prostatectomy, according to a very large series of patients followed at the Cleveland Clinic Foundation and Memorial Sloan-Kettering Cancer Center.

Data Supporting FDA Approval of Eloxatin Presented

December 01, 2002

NEW YORK-Patients with advanced colorectal cancer experienced a significantly better response rate with a combination of oxaliplatin (Eloxatin) and infusional fluorouracil (5-FU)/leucovorin (LV), compared with infusional 5-FU/LV or oxaliplatin alone, Mace Rothenberg, MD, of Vanderbilt University Medical Center, said at the Chemotherapy Foundation Symposium XX. The data, presented for the first time in the United States, were the basis for the recent FDA approval of oxaliplatin.

Federal Court Invalidates FDA’s Pediatric Rule on Drug Safety Tests

December 01, 2002

WASHINGTON-A federal court has invalidated the FDA’s "Pediatric Rule" after concluding that its requirement that drug companies test the safety of adult drugs in children is contrary to the intent of Congress.

Adding Radiotherapy to CHOP Improves Results for Early- or Limited-Stage NHL

December 01, 2002

ORLANDO, Florida-Updateddata from two separate studiesratify earlier results showing thatfollowing CHOP (cyclophosphamide[Cytoxan, Neosar], doxorubicinHCl, vincristine [Oncovin],prednisone) with radiation improvesresults for patients with early-or limited-stage non-Hodgkin’slymphoma (NHL), according todata reported at the 43rd AnnualMeeting of the American Society ofHematology (abstract 3023) .

Optimal-Dose Implants Alone Effective in Low-Risk Pts

December 01, 2002

NEW ORLEANS-Radioactive seed implantation alone continues to prove effective in low-risk prostate cancer, but optimal dose is important in achieving a good outcome, according to a report from Mount Sinai School of Medicine, New York, presented at the American Society for Therapeutic Radiology and Oncology (abstract 55).

Promising Phase II Results for Oncophage in Advanced Melanoma

December 01, 2002

NEW YORK-Antigenics Inc. announced positive final results from a phase II study of the company’s personalized heat shock protein cancer vaccine Oncophage (HSPPC-96) in patients with metastatic melanoma. The study included 39 evaluable patients with stage IV melanoma who underwent surgery to remove tumor tissue, which was used to produce their personalized Oncophage vaccine.

Varian Medical Systems Introduces ‘Acuity’ for Precise Cancer Targeting

December 01, 2002

PALO ALTO, California-Varian Medical Systems, Inc. has received 510(k) clearance from the FDA for Acuity, a new digital imaging product that integrates planning, simulation, and verification software for treating cancer with radiation therapy. It works with Varian’s RPM Respiratory Gating System to track tumor motion during simulation and verification. It is intended to accelerate adoption of intensity modulated radiation therapy (IMRT). By performing patient set-up and treatment plan verification, Acuity frees the linear accelerator to be used exclusively for treatment delivery, Varian said in a press release announcing the new product.

President Wants Curbs on Extensions of Drug Patents

December 01, 2002

WASHINGTON-President Bush has proposed policy changes to restrict the ability of drug companies to extend their patents past their expiration date. Mr. Bush said current federal laws and regulations try to balance the goals of innovation and accessibility.

Parity Status Predicts Breast Cancer Prognosis Later in Life

December 01, 2002

NEW ORLEANS-Having a previous pregnancy improves the prognosis for women who develop early-stage breast cancer later in life, according to a study presented at the 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 152). The findings suggest that a more aggressive treatment approach should be considered for those patients who have not had a pregnancy.

‘Sister Study ’ Looks at Genetic, Environmental Breast Cancer Links

December 01, 2002

RESEARCH TRIANGLE PARK, North Carolina-Researchers have begun the first phase of a long-term, prospective epidemiological study designed to determine the role of genetic, environmental, and lifestyle factors in increasing the risk of breast cancer and several other diseases. The Sister Study is the first long-term follow-up study specifically designed to look at hereditary and environmental risk factors for the disease. It seeks to enroll 50,000 cancer-free women in the United States between the ages of 35 and 74 who have a sister diagnosed with breast cancer.

Fludarabine Combinations Showing Efficacy in Low-Grade Lymphomas

December 01, 2002

LUGANO, Switzerland-Forlow-grade lymphomas, fludarabine(Fludara)-based combination therapymay have greater efficacy thansingle-agent fludarabine, especiallywhen a monoclonal antibody is partof the combination, a series of recentEuropean investigations suggest.The investigations, presentedat the Eighth International Conferenceon Malignant Lymphoma(ICML), show that various combinationtherapies hold promise, althougha lack of coordinationamong non-US study groups hashampered progress somewhat.

Gleevec Effective as First-Line Therapy for CML: IRIS Trial

December 01, 2002

ORLANDO-In a phase IIIstudy, imatinib mesylate (Gleevec),formerly known as STI-571, produceda 96% complete hematologicresponse rate and a 68% completecytogenetic response rate in newly diagnosedchronic myeloid leukemia(CML) patients, Brian Druker, MD,said on behalf of the IRIS (InternationalRandomized Interferon vs STI-571) Study Group at the 38th AnnualMeeting of the American Societyof Clinical Oncology (abstract 1).

Advances in the Management of Lymphoma

December 01, 2002

The past year hasseen a number of excitingadvances in the managementof patients withhematologic malignancies.The principal developmentshave beenthose focused on the conceptof targeted therapy.Though this conceptis not new, continuedevolution in therapeuticstrategies and advancesin knowledge of the biologyof various cellulartargets more than everare bringing about thepotential for new therapieswith additive or synergisticpotential and minimal additional toxicity.

Advances in the Management of Lymphoma

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

New Standards Proposed for Treating Aggressive NHL- Age a Factor

December 01, 2002

HOMBURG, Germany-Afterconducting trials comparingCHOP (cyclophosphamide [Cytoxan,Neosar], doxorubicin HCl,vincristine [Oncovin], prednisone)with and without etoposide andvarying time intervals, the GermanHigh-Grade Non-Hodgkin’s LymphomaStudy Group concluded thatCHOP plus etoposide is the newstandard regimen for younger patientswith low-risk non-Hodgkin’slymphoma (NHL), and CHOP at2-week intervals is the new standardregimen for aggressive NHL in olderpatients.

Federal Court Invalidates FDA’s Pediatric Rule on Drug Safety Tests

December 01, 2002

WASHINGTON-A federal court has invalidated the FDA’s "Pediatric Rule" after concluding that its requirement that drug companies test the safety of adult drugs in children is contrary to the intent of Congress.

Activated Cord Blood Lymphocytes Kill Breast Cancer Cells

December 01, 2002

WASHINGTON-The blood of the human umbilical cord, although often discarded after childbirth, is a "very rich source" of lymphocytes potentially capable of killing cancer cells, according to Shantaram Joshi, PhD, professor of genetics, cell biology, and anatomy, University of Nebraska Medical Center, Omaha.

Rituximab Improves Efficacy of Chemotherapy for Follicular Lymphomas

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

Median PFS Not Yet Reached After 6 Years in Rituximab/CHOP Trial

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

Allogeneic BMT Ups 5-Year EFS in Ph-Negative ALL

December 01, 2002

ORLANDO-Allogeneicbone marrow transplant (BMT) significantlyreduced relapse rates andincreased event-free survival (EFS)rates, but not overall survival, inadults with Philadelphia chromosome(Ph)-negative acute lymphoblasticleukemia (ALL) in first completeremission.

Campath-1H Safe and Effective in Refractory B-CLL

December 01, 2002

ORLANDO-About onethird of “bad prognosis” refractoryB-cell chronic lymphocytic leukemia(B-CLL) patients are salvageablewith alemtuzumab (Campath-1H), according to a compassionateuse study presented at the 43rd AnnualMeeting of the American Societyof Hematology (abstract 1538).

Rituximab Adds Survival Advantage to Fludarabine/Cyclophosphamide for CLL

December 01, 2002

H O U S T O N - A d d i n grituximab (Rituxan) to fludarabine(Fludara)/cyclophosphamide(Cytoxan, Neosar) (FCR) prolongssurvival in patients with relapsedchronic lymphocytic leukemia(CLL), according to GuillermoGarcia-Manero, MD. Dr. Garcia-Manero is assistant professor in theDepartment of Leukemia at TheUniversity of Texas M. D. AndersonCancer Center in Houston. Hepresented updated data on thisstudy in a poster at the 43rd AnnualMeeting of the American Society ofHematology (abstract 2650).

NCCN Updates Hodgkin’s Disease Treatment Guidelines

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

Gene Chips Used to Identify Third Form of Pediatric Leukemia

December 01, 2002

BOSTON-A rare pediatricleukemia, previously thought to bea subset of acute lymphoblastic leukemia(ALL), is actually a distinctform of the disease, according toinvestigators who used gene chipsto create and contrast genetic profilesof cancer cells.

Tandem Transplants Increase CR, Reduce Treatment Mortality in Multiple Myeloma

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

Rituximab Ups Survival in Aggressive and Indolent NHL

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

FDA Approves Zevalin for Use With Rituxan in Refractory NHL Patients

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

New Standards Proposed for Treating Aggressive NHL- Age a Factor

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

Allogeneic BMT Ups Survival in Relapsed CLL Patients

December 01, 2002

ORLANDO-Despite earlymortality risks, HLA-matched siblingbone marrow transplants(BMTs) offer a greater possibility ofcure for patients with relapsedchronic lymphocytic leukemia(CLL) than does chemotherapy, accordingto a report presented at the43rd Annual Meeting of the AmericanSociety of Hematology (abstract2011). A second report (abstract2013) showed that allogeneic transplantled to better event-free survivalthan autologous transplant.

Rituximab Improves Paclitaxel/ Topotecan Salvage Efficacy in NHL

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

Adding Radiotherapy to CHOP Improves Results for Early- or Limited-Stage NHL

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.

FTI Achieves Long-Lasting Responses in MDS Patients

December 01, 2002

SAN FRANCISCO-The investigationalfarnesyl transferase inhibitor(FTI), R115777 (tipifarmib,Zarnestra) causes robust clinical responsesin some patients withmyelodysplastic syndrome (MDS),but these responses are not correlatedwith the drug's ability to inhibitfarnesyl transferase, according to astudy presented at the 93rd AnnualMeeting of the American Associationfor Cancer Research (abstract 4959).

Fludarabine Combinations Showing Efficacy in Low-Grade Lymphomas

December 01, 2002

This special “Annual Highlights” supplement to Oncology NewsInternational is a compilation of the major advances in the managementof the lymphomas and leukemias during 2002, as reported in ONI.Commentaries by the editors, Drs. Gregory Bociek, James Armitage,and Michael Keating, provide perspective and prediction as to howthese developments may affect clinical practice.